Perform Another (Advanced) Search

1.  Newly Approved Drug Therapies (977) Moxatag (amoxicillin), MiddleBrooke Pharmaceuticals,
...Newly Approved Drug Therapies (977) Moxatag (amoxicillin), MiddleBrooke Pharmaceuticals, Drug Information The following information is obtained from various newswires, published medical journal articles, and medical conference presentations. Drug Name: Moxatag (amoxicillin) Company: MiddleBrooke Pharmaceuticals Approval Status: Approved January 2008 Treatment Area: tonsillitis and/or pharyngitis secondary ...
View Page

2.  Newly Approved Drug Therapies (60) Augmentin (amoxicillin/clavulanate), SmithKline Beecham,
...Newly Approved Drug Therapies (60) Augmentin (amoxicillin/clavulanate), SmithKline Beecham, Drug Information The following information is obtained from various newswires, published medical journal articles, and medical conference presentations. Drug Name: Augmentin (amoxicillin/clavulanate) Company: SmithKline Beecham Approval Status: Approved February 1996 Treatment Area: sinusitis, bronchitis, pneumonia General ...
View Page

3.  Newly Approved Drug Therapies (544) Amoxil (amoxicillin), SmithKline Beecham,
...Newly Approved Drug Therapies (544) Amoxil (amoxicillin), SmithKline Beecham, Drug Information The following information is obtained from various newswires, published medical journal articles, and medical conference presentations. Drug Name: Amoxil (amoxicillin) Company: SmithKline Beecham Approval Status: Approved July 1999 Treatment Area: Pediatrics General Information Amoxil, previously ...
View Page

4.  CenterWatch: New Medical Therapies in Disease Category (321), Strep Throat
...Pediatrics/Neonatology August 1, 2005 Advancis issued negative results of their phase III trial of amoxicillin PULSYS , for the treatment of pharyngitis/tonsillitis due to Group A streptococcal infections (strep throat ...
...up. This controlled study enrolled pediatric patients, who received one of two doses of oral amoxicillin PULSYS (475 mg or 775mg once daily) or an oral suspension of penicillin (10 mg ...
View Page

5.  CenterWatch: New Medical Therapies in Disease Category (119), Pharyngitis
...and Par have issued negative results of a phase III trial of their investigational antibiotic Amoxicillin PULSYS , for the treatment of Group A streptococcal pharyngitis/tonsillitis. Trial data failed to meet ...
View Page

6.  CenterWatch: Otolaryngology Approved Drug Therapies
...Meda Pharmaceuticals; For the treatment of seasonal and perennial allergic rhinitis, Approved October 2008 Moxatag (amoxicillin) ; MiddleBrooke Pharmaceuticals; For the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in ...
View Page

7.  CenterWatch: New Medical Therapies in Disease Category (168), Bronchitis
...found that Factive offered a superior option to two other approved antibiotic regimens (gemifloxacin and amoxicillin/clauvulanate): Factive was significantly more efficacious than treatment with gemifloxacin and produced fewer adverse events, and significantly fewer subjects withdrew from Factive treatment than amoxicillin/clauvulanate due to lack of efficacy. Factive also offered a les frequent and/or shorter ...
View Page

8.  Newly Approved Drug Therapies (561) Prevpac, TAP Pharmaceuticals,
...Pharmaceuticals Approval Status: Approved February 1999 Treatment Area: Gastroenterology General Information Prevpac (lansoprazole, clarithromycin and amoxicillin), Rx, has been approved for the eradication of H. pylori to reduce the risk of ...
View Page

9.  Newly Approved Drug Therapies (356) Prevpac, TAP Pharmaceuticals,
...The FDA approved a compliance pack containing Prevacid (lansoprazole) delayed-release capsules, clarithromycin tablets, and amoxicillin capsules for eradication of Helicobacter pylori in patients with duodenal ulcers. Jobson Medical Information • Privacy ...
View Page

10.  CenterWatch: New Medical Therapies in Disease Category (167), Pneumonia
...of NXL103 twice a day, 600mg NXL103 twice a day or 1,000 mg of amoxicillin three times a day, all for seven days. The primary endpoints were the clinical efficacy ...
...doses of NXL103 were effective, with clinical response rates similar to those seen in the amoxicillin group. The response rates were 91.4% in the 500mg NXL103 group; 94.7% in ...
View Page

11.  Newly Approved Drug Therapies (665) Nexium (esomeprazole magnesium), AstraZeneca,
...FDA also approved Nexium for maintenance of healing of erosive esophagitis and, in combination with amoxicillin and clarithromycin, for the eradication of Helicobacter pylori infection in patients with duodenal ulcer disease ...
...pylori eradication rates at four weeks post-therapy were significantly higher in the Nexium plus amoxicillin and clarithromycin group than in a Nexium plus clarithromycin or Nexium alone group. Side Effects ...
View Page

12.  CenterWatch: New Medical Therapies in Disease Category (295), Cold Sores (Herpes Labialis Infections)
...2008. August 21, 2006 Advancis Pharmaceutical announced positive results from a phase III trial of Amoxicillin , for the treatment of pharyngitis/tonsillitis due to Group A streptococcal infections. This double- blind ...
...parallel-group, 50-center non-inferiority trial enrolled 620 subjects who received a 775 mg Amoxicillin PULSYS tablet, once a day, for 10 days or 250 mg of penicillin, four times ...
View Page

13.  CenterWatch: New Medical Therapies in Disease Category (558), Chronic Bronchitis
...inferiority of clinical response compared to a number of approved therapies (including clarithromycin, levofloxacin, trovafloxacin, amoxicillin-clavulanate, ceftriaxone/cefuroxime and ofloxacin). Factive is currently approved to treat AECB and community-acquired ...
View Page

14.  Newly Approved Drug Therapies (19) Cedax (ceftibuten), Schering-Plough,
...beta-lactamases--enzymes produced by bacteria that can render some commonly used antibiotics, such as amoxicillin or penicillin, ineffective. Side Effects Clinical trials revealed a very low incidence of gastrointestinal side ...
View Page

15.  CenterWatch: Pediatrics/Neonatology Approved Drug Therapies
...the treatment of angioedema attacks in adolescents/adults with Hereditary Angioedema, Approved October 2008 Moxatag (amoxicillin) ; MiddleBrooke Pharmaceuticals; For the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in ...
...partial seizures in children (monotherapy for adults), Approved January 2000 Drugs Approved in 1999 Amoxil (amoxicillin) ; SmithKline Beecham; Treatment (antibiotic) for common bacteria, Approved July 1999 Topamax (topiramate) ; Ortho-McNeil Pharmaceutical ...
View Page

16.  CenterWatch: List of Newly Approved Drug Thearapies
...October 2008 Intelence (etravirine) ; Tibotec; For the treatment of HIV-1, Approved January 2008 Moxatag (amoxicillin) ; MiddleBrooke Pharmaceuticals; For the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in ...
...Meda Pharmaceuticals; For the treatment of seasonal and perennial allergic rhinitis, Approved October 2008 Moxatag (amoxicillin) ; MiddleBrooke Pharmaceuticals; For the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in ...
View Page

17.  CenterWatch: New Medical Therapies in Disease Category (179), HIV Infections
...response. August 21, 2006 Advancis Pharmaceutical announced positive results from a phase III trial of Amoxicillin , for the treatment of pharyngitis/tonsillitis due to Group A streptococcal infections. This double- blind ...
...parallel-group, 50-center non-inferiority trial enrolled 620 subjects who received a 775 mg Amoxicillin PULSYS tablet, once a day, for 10 days or 250 mg of penicillin, four times ...
View Page

18.  CenterWatch: New Medical Therapies in Disease Category (465), Bacterial Infections
...trials. August 21, 2006 Advancis Pharmaceutical announced positive results from a phase III trial of Amoxicillin , for the treatment of pharyngitis/tonsillitis due to Group A streptococcal infections. This double- blind ...
...parallel-group, 50-center non-inferiority trial enrolled 620 subjects who received a 775 mg Amoxicillin PULSYS tablet, once a day, for 10 days or 250 mg of penicillin, four times ...
View Page

19.  Newly Approved Drug Therapies (853) Ketek (telithromycin), Sanofi-aventis,
...up of 75.3% compared with 74.5% for subjects who received the comparator drug (amoxicillin/clavulanic acid). Data showed that subjects who received Ketek showed a clinical cure rate at ...
...up of 86.1% compared with 82.1% for subjects who received the comparator drug (amoxicillin/clavulanic). Side Effects Adverse events associated with the use of Ketek may include (but are ...
View Page

20.  CenterWatch: New Medical Therapies in Disease Category (372), Vaccines
...response. August 21, 2006 Advancis Pharmaceutical announced positive results from a phase III trial of Amoxicillin , for the treatment of pharyngitis/tonsillitis due to Group A streptococcal infections. This double- blind ...
...parallel-group, 50-center non-inferiority trial enrolled 620 subjects who received a 775 mg Amoxicillin PULSYS tablet, once a day, for 10 days or 250 mg of penicillin, four times ...
View Page